Semi-synthetic glycopeptide antibacterials (Q35586461)

9 August 2017

1 reference

title

Semi-synthetic glycopeptide antibacterials (English)

1 reference

9 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14622994

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

3 April 2024

pharmaceutical science

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

3 April 2024

author name string

J. Kevin Judice

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14622994

3 April 2024

John L. Pace

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14622994

3 April 2024

language of work or name

English

0 references

publication date

1 December 2003

1 reference

full work available at URL

9 August 2017

https://api.elsevier.com/content/article/PII:S0960894X03009442?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

https://api.elsevier.com/content/article/PII:S0960894X03009442?httpAccept=text/plain

3 April 2024

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Bioorganic & Medicinal Chemistry Letters

3 April 2024

published in

1 reference

9 August 2017

13

1 reference

9 August 2017

4165-4168

1 reference

9 August 2017

23

1 reference

Antibiotic resistance in gram-positive bacteria: epidemiological aspects

9 August 2017

1

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Antibiotic resistance: lessons for the future

3 April 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.

3 April 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Limitations of presently available glycopeptides in the treatment of Gram-positive infection

3 April 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

3 April 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin

3 April 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene

3 April 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium

3 April 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Structure-activity relationships of vancomycin-type glycopeptide antibiotics

3 April 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci

3 April 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala.

3 April 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate

3 April 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Antibacterial activity of G6-quaternary ammonium derivatives of a lipophilic vancomycin analogue

3 April 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Novel semi-synthetic glycopeptide antibiotics active against methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE): doubly-modified water-soluble derivatives of chloroorienticin B.

3 April 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Mechanism of action of oritavancin and related glycopeptide antibiotics

3 April 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Novel glycopeptide antibiotics: N-alkylated derivatives active against vancomycin-resistant enterococci.

3 April 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Synthesis and antibacterial evaluation of N-alkyl vancomycins

3 April 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

A new type of chemical modification of glycopeptides antibiotics: aminomethylated derivatives of eremomycin and their antibacterial activity

3 April 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA.

3 April 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Reversal by a specific peptide (diacetyl-αγ-l-diaminobutyryl-d-alanine) of vancomycin inhibition in intact bacteria and cell-free preparations

3 April 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

A trivalent system from vancomycin.D-ala-D-Ala with higher affinity than avidin.biotin

3 April 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics

3 April 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies

3 April 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

In vitro activity of TD-6424 against Staphylococcus aureus

3 April 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.

3 April 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania

3 April 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.

3 April 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model

3 April 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates

3 April 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study

3 April 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic

3 April 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.BMCL.2003.08.067

3 April 2024

Identifiers

1 reference

9 August 2017

1 reference